Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Current Deferred Revenue (2016 - 2024)

Lifecore Biomedical, Inc. \De\ has reported Current Deferred Revenue over the past 14 years, most recently at $9.0 million for Q4 2024.

  • Quarterly results put Current Deferred Revenue at $9.0 million for Q4 2024, up 8.52% from a year ago — trailing twelve months through Nov 2024 was $9.0 million (up 8.52% YoY), and the annual figure for FY2024 was $10.6 million, up 51.28%.
  • Current Deferred Revenue for Q4 2024 was $9.0 million at Lifecore Biomedical, Inc. \De\, down from $9.3 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for LFCR hit a ceiling of $10.6 million in Q2 2024 and a floor of $287000.0 in Q2 2021.
  • Median Current Deferred Revenue over the past 5 years was $1.1 million (2021), compared with a mean of $3.6 million.
  • Biggest five-year swings in Current Deferred Revenue: plummeted 76.67% in 2020 and later surged 1150.81% in 2023.
  • Lifecore Biomedical, Inc. \De\'s Current Deferred Revenue stood at $297000.0 in 2020, then surged by 225.59% to $967000.0 in 2021, then fell by 24.41% to $731000.0 in 2022, then surged by 1035.43% to $8.3 million in 2023, then rose by 8.52% to $9.0 million in 2024.
  • The last three reported values for Current Deferred Revenue were $9.0 million (Q4 2024), $9.3 million (Q3 2024), and $10.6 million (Q2 2024) per Business Quant data.